Sponsor Dossier
UCB
Sponsor Dossier for UCB. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: BIMZELX
- Brand: BRIVIACT
- Brand: CIMZIA
- Brand: FINTEPLA
- Brand: KEPPRA
- Brand: NEUPRO
- Brand: RYSTIGGO
- Brand: VIMPAT
- Device (sponsor): Swab
About
UCB Pharma Division of UCB is an Australian Private Company with ABN 48005799208, registered in Victoria. The entity is active and registered for GST.
Portfolio
UCB Pharma Division of UCB holds ten brands on the ARTG, with nine indexable brands and nine brands with Product Information on file. Six brands have at least one PBS-listed item, nine brands have PBAC outcomes on record, and five brands have AusPARs on record. Notable brands include BIMZELX, BRIVIACT, CIMZIA, FINTEPLA, KEPPRA, NEUPRO, RYSTIGGO, VIMPAT, XYZAL and ZILBRYSQ.
Therapeutic focus —
Neurology: 7 brands — Immunology: 2 brands — Respiratory: 1 brand
PBS footprint
Six brands in UCB Pharma Division of UCB's portfolio have at least one PBS-listed item, with the latest PBS schedule date touched on 1 May 2026.
Regulatory activity
The most recent PBAC outcome for UCB Pharma Division of UCB was recorded on 1 November 2025, with nine brands holding PBAC outcomes on record. The latest AusPAR was dated 28 January 2025, with five brands holding AusPARs on record.